0 followers
CeleCor Therapeutics develops a RUC-4 novel small molecule inhibitor designed to be the first point of contact treatment for segment elevated myocardial infarction. The molecule inhibitor uses a thrombolytic agent for percutaneous coronary intervention that can be administered subcutaneously by auto... Read more
Robert S. Hillman
ARS Pharmaceuticals
1 follower
Calico
6 followers
Watchmaker Genomics
3 followers
Tessera Therapeutics
2 followers
Caribou Biosciences
2 followers
Vera Therapeutics
2 followers
Immunome
2 followers
Ambience Healthcare
2 followers
EpiVax, Inc.
2 followers
Merck
232 followers
Generate Biomedicines
3 followers
Explore companies